API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
The agreement, Blau’s most recent move into the biosimilars market, is a multi-product and multi-year deal to develop products and licenses IP for four biosimilar assets targeting indications in oncology, inflammation, and blood disorders.
Lead Product(s): Erythropoietin EPO
Therapeutic Area: Hematology Product Name: rHuEPO
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Blau Farmaceutica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 25, 2022